R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.

R&D Investment Trends: A Decade of Innovation

In the competitive landscape of pharmaceutical innovation, research and development (R&D) spending is a critical indicator of a company's commitment to future growth. Over the past decade, Amicus Therapeutics, Inc. and Perrigo Company plc have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Amicus Therapeutics has shown a remarkable increase in R&D spending, peaking in 2020 with a 547% rise from its 2014 levels. This surge underscores Amicus's aggressive pursuit of innovation, particularly in the field of rare diseases. Conversely, Perrigo Company plc's R&D expenses have remained relatively stable, with a slight decline of 20% from 2018 to 2023, reflecting a more conservative approach.

These trends highlight the strategic differences between the two companies, offering insights into their future trajectories in the ever-evolving pharmaceutical industry.